Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A, Capasso A, Heltai S, Taccetti C, Albi E, Herishanu Y, Haggenburg S, Chatzikonstantinou T, Doubek M, Kättström M, Giannopoulos K, Simkovic M, Moreno C, Massaia M, Bumbea H, Alshemmari S, Ranghetti P, Perotta E, Martini F, Sant'Antonio E, Colia M, Combi C, Levi S, Kater AP, Hazenberg M, Nijhof IS, Hofsink Q, Demosthenous C, Kotaskova J, Zaleska J, Vrbacky F, Raya AM, Bisogno D, Tripoli IE, Popov VM, Roman V, Stavroyianni N, Karypidou M, Scarano E, Locatelli M, Frenquelli M, Scarfò L, Stamatopoulos K, Ghia P. Campanella A, et al. Among authors: nijhof is. Am J Hematol. 2024 Apr;99(4):745-750. doi: 10.1002/ajh.27218. Epub 2024 Jan 24. Am J Hematol. 2024. PMID: 38264829
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: nijhof is. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: nijhof is. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
Groen K, Stege CAM, Nasserinejad K, de Heer K, van Kampen RJW, Leys RBL, Thielen N, Westerman M, Wu KL, Ludwig I, Issa DE, Velders GA, Vekemans MC, Timmers GJ, de Boer F, Tick LW, Verbrugge A, Buitenhuis D, Cunha SM, van der Spek E, de Waal EGM, Sohne M, Sonneveld P, Nijhof IS, Klein SK, van de Donk NWCJ, Levin MD, Ypma PF, Zweegman S. Groen K, et al. Among authors: nijhof is. EClinicalMedicine. 2023 Aug 29;63:102167. doi: 10.1016/j.eclinm.2023.102167. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37680948 Free PMC article.
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Rots N, van Beek J, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. Hofsink Q, et al. Among authors: nijhof is. EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. EClinicalMedicine. 2023. PMID: 37337616 Free PMC article.
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM, Pennings ERA, Kos M, Mutsaers PGNJ, Lugtenburg PJ, van Meerten T, van Doesum JA, Minnema MC, Jak M, van Dorp S, Vermaat JSP, van der Poel MWM, van Oijen MGH, Kuipers MT, Nijhof IS, Kersten MJ. Spanjaart AM, et al. Among authors: nijhof is. JCO Oncol Pract. 2023 Mar;19(3):e407-e416. doi: 10.1200/OP.22.00501. Epub 2022 Dec 12. JCO Oncol Pract. 2023. PMID: 36508702 Free PMC article.
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Zweegman S, Kater AP, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, Beaumont T, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI Study Team. Haggenburg S, et al. Among authors: nijhof is. JAMA Oncol. 2022 Oct 1;8(10):1477-1483. doi: 10.1001/jamaoncol.2022.3227. JAMA Oncol. 2022. PMID: 35951338 Free PMC article.
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.
Huygens S, Hofsink Q, Nijhof IS, Goorhuis A, Kater AP, Te Boekhorst PAW, Swaneveld F, Novotný VMJ, Bogers S, Welkers MRA, Papageorgiou G, Rijnders BJ, Heijmans J. Huygens S, et al. Among authors: nijhof is. J Infect Dis. 2023 Jan 11;227(2):206-210. doi: 10.1093/infdis/jiac334. J Infect Dis. 2023. PMID: 35921542 Free PMC article. Clinical Trial.
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, de Rooij DM, van Meerloo J, Cloos J, Kootstra NA, Wouters D, Weijers SS, van Leeuwen EMM, Bontkes HJ, Tonouh-Aajoud S, Heemskerk MHM, Sanders RW, Roelandse-Koop E, Hofsink Q, Groen K, Çetinel L, Schellekens L, den Hartog YM, Toussaint B, Kant IMJ, Graas T, de Pater E, Dik WA, Engel MD, Pierie CRN, Janssen SR, van Dijkman E, Poniman M, Burger JA, Bouhuijs JH, Smits G, Rots NY, Zweegman S, Kater AP, van Meerten T, Mutsaers PGNJ, van Doesum JA, Broers AEC, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS. Haggenburg S, et al. Among authors: nijhof is. Blood Adv. 2022 Mar 8;6(5):1537-1546. doi: 10.1182/bloodadvances.2021006917. Blood Adv. 2022. PMID: 35114690 Free PMC article. Clinical Trial.
37 results